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Oxygen deliveryAbstract Background and objectives: Our study seeks to evaluate the effects of olprinone on
hemodynamics and oxygen delivery on weaning from cardiopulmonary bypass (CPB) and to com-
pare the effects of olprinone and milrinone.
Methods: We retrospectively reviewed 50 pediatric patients administered either olprinone or milri-
none on weaning from CPB during cardiac surgery. At 0, 15, 30, 60, 90, and 120 minutes (min) after
separation from CPB, we collected data on hemodynamics and oxygen delivery. At the same time
points, we also recorded the doses of cardiovascular-acting drugs used concomitantly. We analyzed
differences among measurement points by one-way ANOVA and differences between two agents
groups by two-way ANOVA.
Results: Olprinone increased systolic blood pressure (sBP) at 120 min in biventricular repair (BV)
and from 90 min in Fontan-type operation (FO). Olprinone produced signiﬁcant stepwise tapering
of dopamine from 60 min and dobutamine from 90 min in BV. For BV, olprinone signiﬁcantly
increased central venous oxygen saturation from 30 min; oxygen excess factor at 30 and 120 min;
and cerebral tissue oxygen index from 30 min, except at 60 min. Except for a signiﬁcant increase
in sBP and signiﬁcant tapering of DOA dose at 120 min in BV, milrinone had no effect on any
parameters in either type of operation. Comparisons of the two agent groups showed no signiﬁcant
difference in any parameters.
344 S. Kurokawa et al.Conclusion: Olprinone stabilizes circulation and improves oxygen delivery during BV pediatric car-
diac surgery. While olprinone may have stronger effects than milrinone in BV, the two agents were
comparable for FO.
ª 2013 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Anesthesiologists.
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Several studies attest to the usefulness of milrinone in stabiliz-
ing circulation or improving outcomes in pediatric cardiac sur-
gery. Chang et al. report that administering milrinone in
neonates with low cardiac output syndrome (LOS) after car-
diac surgery signiﬁcantly lowers systemic vascular resistance
(SVR) and pulmonary vascular resistance (PVR) while
improving cardiac index (CI) [1]. Bailey et al. demonstrated
that a loading dose of milrinone resulted in an 18% mean in-
crease in CI after separation from cardiopulmonary bypass
(CPB) during cardiac surgery in children aged from 3 to
22 months [2]. A large multi-center study in North America
(the PRIMACORP study) showed that high-dose milrinone
signiﬁcantly reduced mortality and incidence of LOS after
pediatric cardiac surgery. The PRIMACORP study also
showed that even low-dose milrinone tends to reduce mortality
and LOS development, although not at statistically signiﬁcant
levels [3]. The efﬁcacy of milrinone in the ﬁeld of congenital
heart disease is now well recognized.
Olprinone, another phosphodiesterase-3 (PDE-3) inhibitor
developed in Japan in 1996, is currently available for clinical
use. Several studies show olprinone signiﬁcantly reduces SVR
and signiﬁcantly increases CI during or after coronary artery
bypass graft or valve surgery in adults [4–7]. However, there
is little current data on the potential effects of olprinone on
hemodynamics and oxygen delivery for pediatric cardiac sur-
gery. The present study seeks to evaluate the effects of olpri-
none on these parameters and to compare olprinone to
milrinone on weaning from CPB.
2. Methods
2.1. Materials
We retrospectively reviewed pediatric patients administered
PDE-3 inhibitors, either olprinone or milrinone, on weaning
from CPB during cases of cardiac surgery performed at the
Tokyo Women’s Medical University Hospital from February
2009 to December 2010. Our policies call for administering
PDE-3 inhibitors in patients with congestive heart failure
(CHF) or pulmonary hypertension (PH) preoperatively and
in patients regarded to be at high risk of LOS postopera-
tively. Our infusion standards call for initiating continuous
infusion, either olprinone (at 0.3 lg/kg/min) or milrinone
(at 0.5 lg/kg/min) with no loading dose immediately after
the release of the aortic cross-clamping or, in the absence
of aortic cross-clamping, immediately upon completion of
surgical procedures. The study excluded all patients who
failed to meet these standards in any way. The study also
excluded patients exhibiting any change in infusion rates
by the end of data collection (120 minutes (min) after sepa-
ration from CPB). This study was approved by the institu-
tional ethics committee with a waiver of the requirementto obtain written informed consent from parents or guard-
ians of the studied patients.
2.2. Anesthesia
General anesthesia was induced either by inhalation of sevoﬂu-
rane or intravenous midazolam. Anesthesia was maintained
through a combination of inhaled sevoﬂurane and intravenous
fentanyl. Our standards of anesthesia allow administration of
high-dose fentanyl (minimum of 50–100 lg/kg) to patients
with moderate to severe PH preoperatively and to patients
judged to be at high risk of LOS postoperatively. We adminis-
tered lower-dose fentanyl (less than 50 lg/kg) to the remaining
patients. We conﬁrmed that all patients in this study met these
standards.
2.3. Hemodynamic data
Wegathered hemodynamic data, including blood pressure (BP),
heart rate (HR), and central venous pressure (CVP) at 0 (com-
pletion of separation from CPB), 15, 30, 60, 90, and 120 min
after separation from CPB. Since both the normal range and
the targeted values of these parameters varied with the patients’
age and pathophysiology, we determined the changes from val-
ues at separation from CPB as percentage values.
We recorded the doses of the cardiovascular active drugs
used concomitantly at the same time points at which hemody-
namic data were collected (0, 15, 30, 60, 90, and 120 min after
separation from CPB) and calculated the catecholamine index
at each time point by applying the following formula:
Catecholamineindex¼ dopaminedoseþdobutaminedose
þ100noradrenalinedose
þ100adrenalinedose
ðdosesofallagentsareshowninlg=kg=minÞ2.4. Oximetric data
We gathered venous oxygen saturation (ScvO2) measured via a
PediaSat central venous catheter (Edwards Lifesciences, USA)
placed in the superior vena cava at 0, 15, 30, 60, 90, and
120 min after separation from CPB and calculated the oxygen
excess factor, omega (X), by substituting into the following
formula the values for ScvO2 and oxygen saturation on pulse
oximetry (SpO2) at each measurement point.
X ¼ SpO2=ðSpO2  ScvO2Þ
We routinely monitored cerebral tissue oxygen index (TOI) by
NIRO (NIRO 300; Hamamatsu Photonics, Japan) for all pa-
tients who underwent cardiac surgery. For most (but not all)
cases during the study period, we also monitored cerebral tis-
sue oxygen saturation (rSO2) by INVOS (INVOS 5100; Soma-
netics, USA). We gathered data on TOI and rSO2 at each
measurement point.
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Data are expressed as mean plus–minus standard deviation or
median with range. Between the olprinone group and the mil-
rinone group for either operation, and between biventricular
repair cases and Fontan-type operation cases among either
agent group, we applied an unpaired t-test and Chi-square test
to compare data on patient demographics and preoperative
examinations. We applied one-way analysis of variance (ANO-
VA) followed by Bonferroni’s multiple comparison test to ana-
lyze differences between values at separation from CPB in
hemodynamic and oximetric parameters. To analyze differ-
ences in hemodynamic and oximetric parameters between the
olprinone group and milrinone group, we used two-way ANO-
VA followed by Bonferroni correction for multiple compari-
sons. A p< 0.05 was considered statistically signiﬁcant.
3. Results
Our study enrolled 50 patients who met our standards for PDE-
3 inhibitor infusion. Of these patients, 29 were administered
olprinone and 21 administered milrinone. In the olprinone
group, 19 patients underwent biventricular repair; 10 underwent
the Fontan-type operation. In the milrinone group, 14 under-
went biventricular repair and 7 the Fontan-type operation.
3.1. Demographic data and data on both patient preoperative
cardiac function and pulmonary condition
We collected data on cardiac function and pulmonary condi-
tion at the most recent preoperative echocardiography or car-
diac catheterization. Table 1 summarizes this data and the
demographic data. We observed no signiﬁcant differences be-
tween the olprinone group and milrinone group in any param-
eter for either operation. Likewise, we observed no signiﬁcant
differences between data for the biventricular repair cases and
data for Fontan-type operation cases between the agent
groups.
3.2. Changes in hemodynamic parameters
Olprinone did not affect HR or diastolic BP in either the
biventricular repair group or in the Fontan-type operation
group. Systolic BP was signiﬁcantly increased at 120 min after
separation from CPB in the biventricular repair group and
from 90 min after separation from CPB in the Fontan-type
operation group. In the biventricular repair group alone,
CVP was signiﬁcantly elevated from 90 min after weaning
from CPB (Fig. 1).
Milrinone had no effect on parameters in either operation
group, with the exception of a signiﬁcant increase in systolic
BP at 120 min after weaning from CPB in the biventricular re-
pair group (Fig. 1).
Comparisons of the two agents showed no differences in
either parameter for either operation (Fig. 1).
3.3. Changes in oximetric parameters
No PediaSat catheter was used in 5 cases in the olprinone
group (3 biventricular repair and 2 Fontan-type operation)and 4 cases in the milrinone group (2 for each procedure type).
From rSO2 analysis, we excluded 10 cases in the olprinone
group (9 biventricular repair and 1 Fontan-type operation)
and all but 6 Fontan-type cases in the milrinone group. This
was done because no probe had been applied or due to the
unreliability suggested by extremely high values (exceeding
95%). We also excluded from TOI analysis 8 cases––5 in the
olprinone group (4 biventricular repair and 1 Fontan-type
operation) and 3 in the milrinone group (2 biventricular repair
and 1 Fontan-type operation)––due to unstable TOI values
likely attributable to unstable attachment of probes to the pa-
tient forehead.
Olprinone signiﬁcantly increased ScvO2 from 30 min after
weaning from CPB and X at 30 min and 120 min after weaning
from CPB. Additionally, olprinone increased TOI starting
30 min, except at 60 min, after weaning from CPB in the biven-
tricular repair group. The agent had no effect on any parame-
ters for the Fontan-type operation group (Fig. 2).
Milrinone did not affect parameters in either type of oper-
ation (Fig. 2).
Comparisons of the two agents indicate that olprinone pro-
duced a signiﬁcantly greater increase from baseline (0 min) for
both ScvO2 and X at 30 min and 120 min after weaning from
CPB in biventricular repair cases, but no signiﬁcant difference
in any parameters for Fontan-type operation cases (Fig. 2).
3.4. Infused doses of other cardiovascular drugs administered
concomitantly
All patients in our study received dopamine and nitroglycerine.
Dobutamine was administered to 19 patients in the olprinone
group, including 14 biventricular repair cases and 5 Fontan-
type operation cases, and to 12 patients in the milrinone group,
including 9 biventricular repair cases and 3 Fontan-type oper-
ation cases. The frequency of use of these drugs was compara-
ble for the olprinone group and milrinone group for both types
of operations. These drugs aside, only 3 biventricular repair
cases in the olprinone group were administered isoproterenol,
up to a maximum dose of 0.01 lg/kg/min, due to high-degree
atrioventricular block. Two of the 3 patients received a very
small dose of the agent (up to 0.005 lg/kg/min) for a brief
duration (approximately 30 min).
In the biventricular repair group but not in the Fontan-type
operation group, olprinone produced signiﬁcant stepwise
tapering of dopamine from 60 min, dobutamine from 90 min,
and of the catecholamine index starting 60 min after weaning
from CPB. In contrast, milrinone reduced dopamine only at
120 min after weaning from CPB (Fig. 3). Neither agent signif-
icantly affected the dose of the other cardiovascular-acting
drugs in the Fontan-type operation group (Fig. 3).
Comparisons of the two agents showed no differences in the
doses of the other drugs used concomitantly at same time point
(Fig. 3).
4. Discussion
To the best of our knowledge, this study is the ﬁrst to investi-
gate the effects of olprinone on both hemodynamics and oxy-
gen delivery during pediatric cardiac surgery. Our study
showed that olprinone is effective in stabilizing circulation
and improving oxygen delivery after weaning from CPB in
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Figure 1 Effects of olprinone and milrinone on hemodynamic parameters. Olprinone produced signiﬁcant increases in sBP at 120 min
for biventricular repair (*p< 0.05 vs. Olp 00) and from 90 min for the Fontan-type operation ( p< 0.05 vs. Olp 00 and Olp 150). CVP was
elevated from 90 min only for biventricular repair (*p< 0.05 vs. Olp 00). Milrinone did not affect parameters in either operation group,
except for a signiﬁcant increase in sBP at 120 min for biventricular repair (Ip < 0:05 vs. Mil 00). Comparisons of the two agents showed no
differences in any of the parameters for either operation.
Olprinone in pediatric cardiac surgery 347cases of biventricular repair. We found that olprinone had sim-
ilar results in stabilizing circulation and improving oxygen
delivery in Fontan-type operations, but not at statistically sig-
niﬁcant levels.
A previous study evaluated the effects of olprinone and mil-
rinone on CI, SVR, and PVR after pediatric cardiac surgery in
the ICU by the thermodilution technique, showing that both
olprinone and milrinone prevented CI deterioration without
affecting HR and that both agents signiﬁcantly reduced
SVR, while milrinone reduced PVR more potently than olpri-none [8]. Although our study did not measure cardiac output
directly, we evaluated ScvO2 and X. Li et al. report that both
ScvO2 and X correlate signiﬁcantly with systemic blood ﬂow as
well as oxygen delivery in neonates after the Norwood opera-
tion [9]. In particular, they observed a good correlation be-
tween X and oxygen delivery [9]. Two studies set in ICUs,
one of newborns and infants excluding cases of brain injury
[10] and the other of children following corrective surgery
for non-cyanotic congenital heart disease [11], indicate that
TOI correlates moderately with SvO2. Tortoriello et al. showed
Figure 2 Effects of olprinone and milrinone on oximetric parameters. Olprinone signiﬁcantly increased ScvO2 from 30 min and X at
30 min and 120 min after weaning from CPB (*p< 0.05 vs. Olp 00). From 30 min (except at 60 min), it also increased TOI in cases
involving biventricular repair (*p< 0.05 vs. Olp 00), while the agent had no effect on any parameters for the Fontan-type operation.
Milrinone did not affect any parameters for either type of operation. Comparisons of the two agents showed a signiﬁcantly greater
increase in ScvO2 and X at 30 min and 120 min in the olprinone group in biventricular repair cases (
p< 0.05 Olp vs. Mil), but no
signiﬁcant difference in any of the parameters for the Fontan-type operation.
348 S. Kurokawa et al.that rSO2 correlates moderately with SvO2 in duration from
after weaning from CPB to 6 hours after admission to ICU
in cases of pediatric cardiac surgery [12].
In our study, olprinone in the biventricular repair group in-
creased systolic BP with no effects on HR. Before the increase
in systolic BP, we observed tapering of the concomitantly used
dopamine dose and increases in ScvO2, X, and TOI concurrent
with achievement of effective blood concentrations of olpri-
none. A previous study involving the 13 subjects enrolled in
both the current and previous studies conﬁrmed that the olpri-none infusion regimen achieved effective plasma olprinone
concentrations within 30 min after separation from CPB (or
within 60 min after the initiation of infusion) [13]. We did
not set restrictive criteria for tapering in doses of the concom-
itantly used catecholamines. In principle, doses were tapered
once the targeted values in circulatory parameters (given the
patient’s age and pathophysiology) had been achieved and
once transesophageal echocardiography conﬁrmed normal
ventricular contraction. Thus, olprinone must induce an in-
crease in CI and reductions in SVR, enabling tapering in doses
Figure 3 Doses of concomitantly used inotropes and vasodilator. Olprinone produced signiﬁcant stepwise tapering of both dopamine
from 60 min (*p< 0.05 vs. DOA 00 and 150, p< 0.05 vs. DOA 00, 150, and 300), dobutamine from 90 min (Ip < 0:05 vs. DOB 00, 150, and
300), and the resulting catecholamine index from 60 min after weaning from CPB only for biventricular repair. Milrinone reduced
dopamine doses only at 120 min (p< 0.05 vs. DOA 00). Neither agent affected the doses of other cardiovascular-acting drugs for the
Fontan-type operation. Comparisons of the two agents showed no difference in doses of the other drugs used concomitantly at any time
point.
Olprinone in pediatric cardiac surgery 349of the concomitantly used catecholamines, while improving
oximetric parameters and maintaining hemodynamic parame-
ters. CVP rose in biventricular repair patients starting at
around 90 min after weaning from CPB. In approximately
two-thirds of the patients in this group, the sternum was closed
from 60 to 90 min after weaning from CPB. In the remaining
patients, the sternum was closed at a time point exceeding
90 min after weaning from CPB. While the elevation in CVP
was small and temporary in most the patients, it nonetheless
appeared to persist for a non-negligible duration.
In our series, rSO2 exceeded TOI. These parameters varied
widely from case to case. Dullenkopf et al. report that absolute
values of rSO2 and TOI vary widely among individuals, even at
baseline [14]. They also demonstrate that rSO2 values, particu-
larly with pediatric sensors, are signiﬁcantly higher than TOI
values [14]. These ﬁndings suggest our data on cerebral rSO2
and TOI are sufﬁciently reliable to estimate systemic blood
ﬂow and oxygen delivery indirectly.
We also observed the abovementioned trends in hemody-
namic and oximetric parameters during olprinone administra-
tion in cases of Fontan-type operations, but not at
statistically signiﬁcant levels. In Fontan physiology, selec-
tively reducing PVR is a key factor in increasing CI and oxy-
gen delivery, differing in this respect from biventricular
circulation. A study has demonstrated that olprinone reduces
PVR insigniﬁcantly compared to placebo [8]. Moreover, in
our series, patients in the Fontan-type operation group were
more likely to have small ejection fraction and elevated end-
diastolic pressure in the ventricle than patients in the biven-
tricular repair group. These may account for the less potent
effects of olprinone on circulation and oxygen delivery in
Fontan-type operations.We observed similar but weak trends during milrinone
administration for both types of operations. Although we
did not conﬁrm effective blood concentrations for milrinone,
our infusion rate was the same as in the previous study com-
paring the effects of olprinone and milrinone on circulation
after pediatric cardiac surgery [8]; additionally, our infusion
rate exceeded the rate used for low-dose cases in the PRIMA-
CORP study, even when accounting for the loading dose used
in the PRIMACORP study [3]. Demographic data and data
for both patient preoperative cardiac function and pulmonary
condition were comparable for the two agent groups. Compar-
isons of the two agents indicated signiﬁcantly greater improve-
ment in two oximetric parameters, ScvO2 and X, in the
olprinone group during biventricular repair. In addition to
early stepwise tapering of concomitantly used cathecolamines
in the olprinone group, this suggests that olprinone might be
more potent in stabilizing circulation and improving oxygen
delivery in biventricular repair. The two agents were equally
effective for Fontan-type operation cases.
4.1. Limitations
Our study is subject to several limitations. First, it was con-
ducted in retrospective manner. Second, the sample size was
small. Statistical power analysis failed to reach 0.8 for any oxi-
metric parameter but exceeded 0.8 for all increases in hemody-
namic parameters and for the tapering of the DOA dose for
biventricular repair in the olprinone group. In addition, the
study subjects did not have uniform backgrounds. Age, diag-
nosis, pathophysiology, and severity of illness varied widely.
Moreover, surgical insults, including operation time, CPB
time, and aortic cross-clamping time, differed case by case.
350 S. Kurokawa et al.These factors may affect the magnitude of the effects of olpri-
none or milrinone on circulation and oxygen delivery. Ideally,
these factors should be controlled in a study with a small sam-
ple size. Lastly, MUF was applied to the majority of the cases
in our study. MUF may remove various inﬂammatory media-
tors such as cytokines [15] and may subsequently improve pa-
tient hemodynamic states [16]. Due to the absence of a control
group, our study was unable to clearly distinguish the effects of
MUF on hemodynamics and oxygen delivery from the effects
of PDE-3 inhibitors.
In summary, olprinone stabilized circulation and improved
oxygen delivery in cases of biventricular repair. The magnitude
of olprinone’s effects may exceed milrinone for biventricular
repair cases and may equal milrinone for Fontan-type cases.
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